BPC-157: What the Research Actually Shows — and What It Doesn’t
BPC-157 is not approved by the FDA for any human use, and no FDA-approved drug product containing BPC-157 exists, as of September 2026. Nearly all of the research on it has been done in animals. A 2025 systematic review of its use in orthopaedic sports medicine found 36 studies: 35 were preclinical (animal or lab) studies and 1 was a clinical (human) study, as of September 2026 (Vasireddi et al., HSS Journal, 2025).
So if you’ve heard BPC-157 described as a proven healing peptide, that isn’t what the research shows. The animal results are notable. What the research can’t tell you yet is whether it works or is safe in people.
What is BPC-157?
BPC-157 is a lab-made peptide, meaning a short chain of amino acids. It’s modeled on a compound found naturally in your stomach’s gastric juice. Its technical name is a “pentadecapeptide,” which just means it’s built from 15 amino acids.
Researchers mostly study it for tissue repair. That includes tendons, ligaments, muscle, bone and the lining of your gut. The core question behind most of the studies is simple: does an injured tissue heal faster or more completely when BPC-157 is given?
The compound occurs naturally in the body, but that tells you where it came from. It doesn’t tell you whether the lab-made version is safe to take.
What does BPC-157 do? What the research shows
In animal studies, BPC-157 has been linked to better healing across several kinds of injury. Researchers saw it in tendons, muscle, ligaments and bone. That pattern is why people are interested. It’s also where the evidence mostly stops, because nearly all of it comes from rats and rabbits.
The studies below are all cited in the 2025 systematic review (PMC12313605). The “reported findings” column summarizes how that review describes each result.
| Study | Species / model | Injury studied | Reported findings (per the review) |
|---|---|---|---|
| Sikiric et al., 1997 | Male Wistar rats | Induced inflammatory arthritis | Less paw inflammation, nodule formation and stiffness |
| Sebecić et al., 1999 | Rabbits | Nonunion bone defect | Results similar to bone marrow injection and bone grafting in healing the defect |
| Staresinic et al., 2003 | Male Wistar rats | Achilles tendon transection | Better tendon structure, function and biomechanics; less inflammation |
| Krivic et al., 2006 | Male Wistar rats | Achilles tendon transection | Better function, biomechanics and tissue structure; the tendon-to-bone defect healed |
| Staresinic et al., 2006 | Male Wistar rats | Quadriceps muscle transection | Better muscle structure, function and biomechanics |
| Novinscak et al., 2008 | Male Wistar rats | Muscle crush injury | Better muscle structure; function restored |
| Cerovecki et al., 2010 | Male Wistar rats | Medial collateral ligament (MCL) transection | Less joint instability and contracture; motor function restored |
| Chang et al., 2011 | Cultured rat tendon tissue and cells (in vitro) | Lab-dish tendon model | More tendon outgrowth, cell migration and cell survival under stress |
| Japjec et al., 2021 | Male Wistar rats | Quadriceps tendon transection | Better tendon structure; less inflammation; the muscle-tendon defect healed |
Across the animal models the review covered, BPC-157 was given as an injection into muscle, into the abdominal cavity or into a vein, and also by mouth. The review states that “no acute lethal or toxic dose was reported” for any of these routes. That finding comes only from animal models. The fact that rats showed no acute toxicity is not evidence that BPC-157 is safe for humans.
The one human study
The only clinical study in the review is Lee et al., 2021. It was a small retrospective study, meaning researchers looked back at patients who had already been treated. The patients had chronic knee pain and received BPC-157 alone by intraarticular injection (injected into the joint). Of 12 patients, 7 reported that their symptoms felt better for more than 6 months (PMC12313605).
This is one study, with 12 people and self-reported results. It had no comparison group, and it wasn’t designed to test effectiveness or safety. It’s a reason to do more research. It doesn’t prove that BPC-157 works in people.
The review’s authors say this themselves. They write that “the lack of clinical outcome and safety data prevents us from proposing evidence-based practice use guidelines” (PMC12313605).
BPC-157 side effects: what we know and what we don’t
In short, no one knows the side effects of BPC-157 in humans, because no study has tested them. The 2025 systematic review found that “no study assessed the safety or adverse events of BPC-157 in humans” (PMC12313605).
That doesn’t mean BPC-157 has no side effects. It means nobody has studied them properly in humans. When no side effects are reported, it’s usually because nobody was measuring.
The U.S. Anti-Doping Agency puts it plainly: “it is unknown if there is a safe dose, or if there is any way to use this substance safely” (USADA). That’s the most accurate summary available as of September 2026. We won’t offer our own risk rating in its place.
There’s a separate concern with the product itself. FDA notes that compounded drugs containing BPC-157 “may pose risk for immunogenicity for certain routes of administration” (FDA). Immunogenicity means the risk that your immune system reacts to the substance. FDA also points to possible problems with peptide-related impurities and with confirming what the active ingredient actually is. So the risk isn’t only about BPC-157 itself. It’s also about whether a given product contains what its label says.
Does BPC-157 affect the heart?
We don’t know. The 2025 systematic review doesn’t report any heart-related findings, and no human study has looked at heart effects. If you have a heart condition, the honest answer is that no human data exists to guide you either way.
Does BPC-157 affect the liver?
The human evidence doesn’t exist here either. The systematic review mentions liver-protective effects in animal models. Those are rat findings. They don’t show how BPC-157 affects a human liver, and no human study has measured it.
Does BPC-157 interact with testosterone?
This is unknown. The systematic review doesn’t address testosterone, and no human study has examined how BPC-157 interacts with testosterone or testosterone therapy. If you’re on hormone therapy, that gap is worth raising with your prescriber before you add anything.
Is it bad to take BPC-157 every day?
No one can answer this with evidence yet. No human study has looked at repeated or long-term use, so nothing shows what daily use does over months or years. That’s also why this page doesn’t suggest any frequency or amount. The data needed to support one doesn’t exist.
Is BPC-157 FDA approved? Where its regulatory status stands
BPC-157’s regulatory status involves several separate agencies. Here’s where each one stands, stated plainly.
FDA approval. BPC-157 is not approved by the FDA for any human use, and no FDA-approved drug product containing BPC-157 exists, as of September 2026.
FDA’s compounding list. BPC-157 appears on FDA’s list of bulk drug substances nominated for use in compounding and later withdrawn by their nominators. FDA records that compounded drugs containing BPC-157 “may pose risk for immunogenicity for certain routes of administration” and may involve complexities in peptide-related impurities and characterization of the active ingredient, as of September 2026 (FDA, Certain Bulk Drug Substances for Use in Compounding).
The July 2026 advisory committee vote. On July 23, 2026, FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend that BPC-157 be added to the 503A bulks list. That’s the list of substances compounding pharmacies may prepare for individual patients. FDA’s own scientific staff had opposed the recommendation. Advisory committee recommendations are non-binding, and FDA had not adopted this one, as of September 2026 (FDA, July 23–24, 2026 PCAC Meeting).
The vote matters, but it’s a recommendation, not a decision. Until FDA acts on it, BPC-157’s compounding status stays as described above.
Sport. BPC-157 is prohibited in sport under the World Anti-Doping Agency’s S0 Non-Approved Substances category, as of September 2026 (USADA).
Military. BPC-157 appears on the Department of Defense Prohibited Dietary Supplement Ingredients List, and is not a dietary ingredient, as of September 2026 (OPSS).
The bottom line
BPC-157 has a notable set of animal studies behind it, mostly on tendon, muscle and ligament repair. In humans, the evidence is one small retrospective study, and no study has measured its safety. Its regulatory status is still changing. The one thing that is settled is that BPC-157 is not FDA-approved for any human use, as of September 2026.
If you’re thinking about BPC-157, the most useful next step is a conversation with a licensed clinician who knows your health history.
FAQs About BPC-157
Is BPC-157 legal?
There isn’t a simple yes or no, because different agencies treat BPC-157 differently. BPC-157 is not approved by the FDA for any human use, as of September 2026. On July 23, 2026, FDA’s Pharmacy Compounding Advisory Committee voted to recommend adding it to the list of substances compounding pharmacies may prepare. That recommendation is non-binding, and FDA had not adopted it, as of September 2026. Separately, BPC-157 is prohibited in sport under the World Anti-Doping Agency’s S0 Non-Approved Substances category, as of September 2026.
Is BPC-157 FDA approved?
No. BPC-157 is not approved by the FDA for any human use, and no FDA-approved drug product containing BPC-157 exists, as of September 2026. A July 2026 FDA advisory committee vote recommended a change to its compounding status, not approval as a drug. That recommendation is non-binding.
Can you buy BPC-157 over the counter?
No. The Operation Supplement Safety (OPSS) program states that BPC-157 cannot be legally prescribed or sold over the counter, as of September 2026. OPSS also notes that it appears on the Department of Defense Prohibited Dietary Supplement Ingredients List and is not a dietary ingredient.
Can peptides fail a drug test?
Yes. In sports drug testing, BPC-157 is prohibited under the World Anti-Doping Agency’s S0 Non-Approved Substances category, according to USADA, as of September 2026. If you’re an athlete subject to anti-doping rules, using BPC-157 can lead to an anti-doping violation.
Is BPC-157 safe?
Nobody knows yet. As of a 2025 systematic review, no study had measured BPC-157’s safety or side effects in humans. USADA states that “it is unknown if there is a safe dose, or if there is any way to use this substance safely.”
This article is for informational purposes only and isn’t medical advice. Talk to a licensed healthcare provider before using any peptide, especially one that’s unapproved or compounded. We don’t yet work with a credentialed medical reviewer — see our editorial policy for what that means for this article.
